Inhaled GM-CSF therapy (molgramostim) demonstrated significant improvements in alveolar-arterial oxygen gradients and functional status in patients with autoimmune PAP in a multicenter randomized controlled trial [18]. This evidence concerns the gene CSF2 and autoimmune pulmonary alveolar proteinosis.